Diginex Targets $9.6 Billion Compliance Market as Shares Plunge Over 30% in a Month

Diginex launches Risk-to-Remedy platform for supply chain human rights due diligence, but stock falls 28% in a week amid missing revenue data and no customer contracts.

The numbers paint a stark picture. On one hand, Diginex is betting on a due-diligence market projected to swell from $3.8 billion in 2025 to $9.6 billion by 2034, fueled by a wave of European regulations. On the other, its stock closed Thursday at $1.04, down 28% over the past week and 33% over the past 30 days. A separate calculation put the monthly decline at more than 40%, with the stock ending the session at $1.05 — a 4.09% drop on the day.

That disconnect between strategy and market reaction lies at the heart of Diginex’s current predicament.

The company announced on June 4 the integration of a new platform called Risk-to-Remedy, designed to digitize human rights due diligence across supply chains. The solution combines three existing components: the LUMEN risk-assessment tool, the APPRISE worker-survey module, and the expertise of The Remedy Project on grievance mechanisms. Rather than relying on supplier self-declarations and annual audits, the system aims to pull verifiable information directly from the supply chain floor.

Diginex highlights the scale of the problem it wants to solve: 86% of forced labor occurs in the private sector, and an estimated 50 million people worldwide are trapped in modern slavery. The company is positioning Risk-to-Remedy not merely as an ESG reporting tool, but as an operational platform that covers procurement, auditing, risk management and regulatory documentation — areas where compliance pressure is mounting fast.

That pressure comes from multiple legal fronts. The EU’s Corporate Sustainability Due Diligence Directive took effect in July 2024, requiring member states to publish national rules by July 2028 and enforce them from July 2029. Germany’s Supply Chain Due Diligence Act already applies to companies with more than 3,000 employees since January 2023 and was extended to firms with at least 1,000 employees from January 2024. Meanwhile, an EU regulation banning products linked to forced labor entered force in December 2024 and will apply from December 2027.

Diginex’s target market numbers, which the company itself cites, have not been independently verified. But the regulatory tailwind is undeniable: corporations need systems that not only identify risks but also document evidence and corrective measures.

Yet the stock shows no sign of responding to the narrative. Technical indicators suggest acute stress. The relative strength index stood at 30.4 in one reading and 30.7 in another — both just above the oversold threshold of 30. Annualized volatility is running at nearly 156%.

The problem, analysts note, is that the product announcement comes with no financial backing. There are no customer names, no contract values, no recurring revenue figures, and no timeline for additional features. The news is strategic, not commercial. Until Diginex converts its platform into measurable revenue, the shares lack a fundamental floor — no matter how large the addressable market looks on paper.